AIM
PCVX icon

Aigen Investment Management’s Vaxcyte PCVX Stock Holding History

Aigen Investment Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,423
Closed -$231K – 889
2025
Q3 		$231K Sell
6,423
-14,676
-70% -$486K 0.04% 626
2025
Q2 		$686K Buy
+21,099
New +$692K 0.09% 326
2025
Q1 		– Sell
-4,538
Closed -$371K – 962
2024
Q4 		$371K Buy
+4,538
New +$451K 0.07% 416

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Aigen Investment Management's PCVX Position: Q4 2025 in Review

Aigen Investment Management sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 6,423 shares — an estimated $231K sold.

Aigen Investment Management first reported a position in PCVX in Q4 2024 and held it in 3 quarters. The position peaked at $686K in Q2 2025. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

  • Aigen Investment Management reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
  • Aigen Investment Management sold 6,423 Vaxcyte shares in Q4 2025, an estimated $231K.
  • Aigen Investment Management first reported a position in Vaxcyte in Q4 2024 and held it in 3 quarters.
  • Aigen Investment Management's Vaxcyte position peaked at $686K in Q2 2025.
  • 295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Aigen Investment Management's 13F filing for Q4 2025, filed 13 Feb 2026.